NASDAQ:REPH - Recro Pharma Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $5.69 -0.03 (-0.52 %) (As of 07/20/2018 02:49 PM ET)Previous Close$5.67Today's Range$5.59 - $5.7652-Week Range$4.78 - $13.05Volume2,500 shsAverage Volume199,458 shsMarket Capitalization$111.56 millionP/E Ratio-2.85Dividend YieldN/ABeta-0.96 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania. Receive REPH News and Ratings via Email Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:REPH CUSIPN/A Webwww.recropharma.com Phone484-395-2470 Debt Debt-to-Equity Ratio2.20 Current Ratio1.78 Quick Ratio1.55 Price-To-Earnings Trailing P/E Ratio-2.85 Forward P/E Ratio-1.84 P/E GrowthN/A Sales & Book Value Annual Sales$71.83 million Price / Sales1.62 Cash FlowN/A Price / CashN/A Book Value$1.51 per share Price / Book3.77 Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-50,080,000.00 Net Margins-74.85% Return on Equity-105.78% Return on Assets-24.06% Miscellaneous Employees256 Outstanding Shares20,510,000Market Cap$111.56 Recro Pharma (NASDAQ:REPH) Frequently Asked Questions What is Recro Pharma's stock symbol? Recro Pharma trades on the NASDAQ under the ticker symbol "REPH." How were Recro Pharma's earnings last quarter? Recro Pharma Inc (NASDAQ:REPH) issued its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.03. The specialty pharmaceutical company earned $19.54 million during the quarter, compared to the consensus estimate of $17.32 million. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. View Recro Pharma's Earnings History. What price target have analysts set for REPH? 7 analysts have issued 12 month price targets for Recro Pharma's stock. Their forecasts range from $9.00 to $19.00. On average, they expect Recro Pharma's share price to reach $13.20 in the next year. This suggests a possible upside of 131.2% from the stock's current price. View Analyst Ratings for Recro Pharma. What is the consensus analysts' recommendation for Recro Pharma? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Recro Pharma's key competitors? Some companies that are related to Recro Pharma include Evelo Biosciences (EVLO), Sinovac Biotech (SVA), Dermira (DERM), ZIOPHARM Oncology (ZIOP), Unum Therapeutics (UMRX), ProMetic Life Sciences (PFSCF), Achillion Pharmaceuticals (ACHN), American Brivision (Holding) (ABVC), Syros Pharmaceuticals (SYRS), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Xeris Pharmaceuticals (XERS), Savara (SVRA), Mersana Therapeutics (MRSN) and MediciNova (MNOV). Who are Recro Pharma's key executives? Recro Pharma's management team includes the folowing people: Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)Mr. Michael Celano, COO & Corp. Sec. (Age 59)Dr. Stewart McCallum, Chief Medical Officer (Age 52)Mr. Ryan D. Lake, Chief Financial Officer (Age 41)Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53) Has Recro Pharma been receiving favorable news coverage? News articles about REPH stock have trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a media sentiment score of 0.08 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 46.52 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are Recro Pharma's major shareholders? Recro Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (9.99%) and Sanders Morris Harris LLC (1.35%). Company insiders that own Recro Pharma stock include Alfred Altomari, Healthcare Master Fun Broadfin, James E Flynn, Karen Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Institutional Ownership Trends for Recro Pharma. Which major investors are buying Recro Pharma stock? REPH stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Healthcare Master Fun Broadfin and Karen Flynn. View Insider Buying and Selling for Recro Pharma. How do I buy shares of Recro Pharma? Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Recro Pharma's stock price today? One share of REPH stock can currently be purchased for approximately $5.71. How big of a company is Recro Pharma? Recro Pharma has a market capitalization of $111.56 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe. How can I contact Recro Pharma? Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected] MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 157 (Vote Underperform)Total Votes: 354MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?